Jay Cutler TRT: Clinical Interpretation of a Bodybuilder's Post-Retirement Hormone Protocol

What Has Jay Cutler Said About TRT?

Jay Cutler has discussed his use of TRT in multiple public forums, including podcast interviews and social media, stating that he uses testosterone to maintain hormonal health after retiring from professional bodybuilding. He has framed the decision as medically supervised and distinct from the performance-enhancing protocols he used during competition. These are self-reported statements, not medical records, and should be treated as such throughout any clinical analysis.

Primary Statements on Record

In a 2022 episode of the "Cutler Cast" podcast and in separate interviews with Generation Iron, Cutler acknowledged openly that TRT is part of his current health regimen. He described working with physicians and stated his goal is quality of life rather than performance. No specific dose, ester, or lab values were disclosed in those sessions.

Because no lab data or prescription records are public, any clinical interpretation here is inference based on published data about retired elite bodybuilders, not a statement about Cutler's specific physiology.

Why Transparency Matters Clinically

Athletes who speak openly about TRT reduce stigma around medically supervised hormone therapy and help distinguish therapeutic use from unmonitored self-administration. The distinction matters because improperly dosed testosterone carries real cardiovascular, hematologic, and hepatic risks, as detailed below.

Why Elite Bodybuilders Frequently Require TRT After Retirement

The hypothalamic-pituitary-gonadal (HPG) axis regulates endogenous testosterone production through a negative feedback loop. When exogenous androgens suppress GnRH and LH secretion for years, the axis can fail to recover fully after cessation.

HPG Axis Suppression: The Mechanism

Gonadotropin-releasing hormone (GnRH) pulses from the hypothalamus drive pituitary LH and FSH release. LH acts on testicular Leydig cells to produce testosterone. Supraphysiologic exogenous androgens suppress GnRH pulsatility through negative feedback, causing LH and FSH to fall toward zero [1]. Prolonged suppression may lead to Leydig cell atrophy and reduced steroidogenic capacity that persists after drug cessation [2].

A 2021 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism found that 37% of former anabolic-androgenic steroid (AAS) users had persistent hypogonadism (total testosterone <300 ng/dL) at a mean of 32 months post-cessation [3]. Recovery, when it occurs, may take two to four years of abstinence, and some men never return to eugonadal levels [4].

Duration and Dose Drive Recovery Odds

A 2019 study in the European Journal of Endocrinology followed 100 male former AAS users and found that duration of use above five years and cumulative dose both independently predicted failure to recover HPG function at 12-month follow-up [5]. Competitive bodybuilders at the professional level commonly use androgens for far longer than five years, which places them in the highest-risk category for permanent suppression.

Clinical Definition of TRT-Appropriate Hypogonadism

TRT is indicated for symptomatic hypogonadism confirmed by laboratory testing, not for cosmetic or performance goals in men with normal testosterone levels.

Diagnostic Criteria Per Endocrine Society Guidelines

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states: "We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally low serum testosterone concentrations" [6]. Two morning fasting total testosterone measurements below 300 ng/dL, drawn on separate days, are required before initiating therapy per that guideline [6].

Symptoms include reduced libido, fatigue, depressed mood, loss of muscle mass, and decreased bone mineral density. A retired bodybuilder who spent years at supraphysiologic testosterone levels may experience these symptoms even at testosterone concentrations that would be considered low-normal in men without prior AAS exposure, because their androgen receptors have been chronically downregulated.

Free Testosterone and SHBG Considerations

Total testosterone alone can be misleading. Sex hormone-binding globulin (SHBG) binds testosterone tightly, and only free or bioavailable testosterone is active at the receptor level. The Endocrine Society guideline recommends measuring free testosterone by equilibrium dialysis when total testosterone falls in the 300 to 400 ng/dL borderline range, particularly in men with conditions that alter SHBG [6]. Aging, obesity, and prior AAS use all affect SHBG levels.

Standard TRT Protocols in Clinical Practice

Multiple FDA-approved testosterone formulations exist. The choice depends on patient preference, tolerability, cost, and the prescribing physician's assessment of cardiovascular and hematologic risk.

Injectable Testosterone Esters

Testosterone cypionate and testosterone enanthate are the most commonly prescribed injectable forms in the United States. Standard TRT dosing ranges from 100 to 200 mg intramuscularly every seven to fourteen days, producing peak serum testosterone of roughly 700 to 1,100 ng/dL at 48 to 72 hours post-injection, falling to trough values near 300 to 500 ng/dL by day fourteen [7]. Weekly injections of 100 mg reduce peak-to-trough variation compared with biweekly protocols and are preferred by many clinicians for hematocrit and symptom stability.

Transdermal and Subcutaneous Options

Testosterone gels (AndroGel 1%, 1.62%; Testim; Vogelxo) deliver 50 to 100 mg/day topically, producing steadier serum concentrations without injection-related peaks. Subcutaneous testosterone pellets (Testopel) are implanted every three to six months and release testosterone at roughly 1.3 mg per pellet per day [8]. The FDA has approved each of these formulations; the full list of approved testosterone products is maintained on the FDA's drug database [9].

Monitoring Requirements on TRT

The Endocrine Society guideline requires monitoring of total testosterone (target 400 to 700 ng/dL mid-interval), hematocrit (hold or dose-reduce if hematocrit exceeds 54%), PSA, and bone mineral density [6]. Hematocrit elevation is the most common adverse effect of TRT. A 2010 meta-analysis in the Journal of Clinical Endocrinology and Metabolism found testosterone therapy increased hemoglobin by a mean of 0.8 g/dL and raised the risk of erythrocytosis (hematocrit >50%) by approximately threefold versus placebo [10].

Cardiovascular Considerations for Former Elite Bodybuilders on TRT

Cardiovascular risk in former AAS users is not the same as in de-novo-hypogonadal men starting TRT for the first time. Decades of supraphysiologic androgen exposure leave structural and functional cardiac changes that alter how TRT risk should be assessed.

Left Ventricular Hypertrophy and Diastolic Dysfunction

A 2017 study in Circulation: Heart Failure compared cardiac MRI data from 140 male weightlifters: 86 current or former AAS users and 54 non-users [11]. Former AAS users showed left ventricular wall thickness and mass significantly exceeding non-using athletes and controls, and 71% met criteria for impaired diastolic function versus 26% of non-users (P<0.001 in that cohort). These structural changes do not fully reverse after cessation.

The TRAVERSE Trial and TRT Cardiovascular Safety

The TRAVERSE trial (N=5,246, mean age 57 years) randomized men with hypogonadism and elevated cardiovascular risk or established cardiovascular disease to testosterone gel 1.62% or placebo for a median of 33 months [12]. The primary endpoint (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) showed non-inferiority of testosterone to placebo (hazard ratio 1.02, 95% CI 0.82 to 1.28) [12]. TRAVERSE enrolled general hypogonadal men, not former elite bodybuilders with pre-existing cardiac remodeling, so the findings apply only partially to Cutler's likely clinical profile.

Physicians managing former professional bodybuilders on TRT should obtain baseline echocardiography, Holter monitoring, and lipid panel before initiating therapy, and repeat cardiac assessment annually.

Lipid Effects

Testosterone therapy reduces HDL cholesterol by approximately 5 to 10% depending on formulation and dose. Injectable esters produce larger HDL decreases than transdermal gel, likely because oral and injectable routes have different hepatic first-pass effects [13]. For a former elite bodybuilder who may already have atherogenic lipid patterns from years of AAS use and high-calorie dieting cycles, this HDL reduction warrants close monitoring and, in some cases, statin co-prescribing.

Differentiating Therapeutic TRT from Performance Enhancement

A repeated theme in Jay Cutler's public statements is that his current testosterone use is therapeutic, not aimed at athletic performance. Clinically, this distinction has meaning.

Dose Is the Key Variable

Therapeutic TRT targets a serum total testosterone of 400 to 700 ng/dL, the mid-normal physiologic range for adult men [6]. Performance-enhancing protocols used in competitive bodybuilding commonly target concentrations of 1,500 to 5,000 ng/dL or higher through stacking multiple anabolic agents. The biological risks, cardiovascular strain, HPG suppression, and erythrocytosis scale with dose, so therapeutic TRT at physician-guided doses carries a fundamentally different risk profile than the protocols used during Cutler's competitive career.

Regulatory and Anti-Doping Context

Cutler retired from the IFBB Pro League before mandatory drug testing became standard practice in the sport. He competes in no sanctioned drug-tested federation at present. Therapeutic Use Exemptions (TUEs) exist in sports with anti-doping oversight; WADA allows TRT under documented hypogonadism, provided testosterone stays within the reference range on test day [14]. This context is relevant for any athlete or coach interpreting his disclosures.

What "Medically Supervised TRT" Should Look Like: A Clinical Standard

For any patient with a history of prolonged AAS use seeking TRT, the workup and monitoring protocol should follow a structured path.

Baseline Evaluation

Before prescribing testosterone, a clinician should confirm:

• Two fasting morning total testosterone values <300 ng/dL drawn at least one week apart
• LH and FSH (expected to be low or low-normal in exogenous-androgen-induced hypogonadism)
• Prolactin to exclude pituitary adenoma
• Complete metabolic panel, CBC, and lipid panel
• PSA for men over 40
• Echocardiogram in men with prior heavy AAS use

The Endocrine Society guideline specifically advises against initiating TRT in men with hematocrit above 54%, untreated severe obstructive sleep apnea, or active prostate cancer [6].

Ongoing Monitoring Schedule

After initiation, monitoring should occur at three months (testosterone level, hematocrit, PSA), then at six months, then annually if stable. If hematocrit exceeds 54%, the dose should be reduced or the injection interval extended. If PSA rises more than 1.4 ng/mL above baseline within 12 months, urology referral is indicated [6].

What Jay Cutler's Case Illustrates for the Broader TRT Conversation

Cutler's willingness to discuss TRT publicly adds a real-world example to the clinical literature on post-AAS hypogonadism. His case, interpreted clinically, reflects a well-documented phenomenon: prolonged supraphysiologic androgen exposure frequently produces HPG axis suppression that does not resolve after cessation, leaving men with genuine, symptomatic hypogonadism that meets guideline criteria for treatment.

The Former-Athlete Patient Profile

Physicians increasingly see former strength athletes, powerlifters, and bodybuilders presenting with fatigue, low libido, depressed mood, and testosterone levels below 300 ng/dL years after stopping AAS. This population benefits from the same evidence-based evaluation pathway as any hypogonadal man, with added attention to cardiovascular surveillance given their structural cardiac history.

Avoiding Overtreatment

One clinical risk in this population is the temptation to push testosterone levels to the high end of the reference range or above, replicating the subjective sense of well-being from former supraphysiologic exposure. Guideline-concordant TRT targets mid-normal ranges. Physicians should counsel this population that the therapeutic goal is symptom resolution and metabolic health, not re-creating peak competitive physiology.

A 2020 review in the Endocrine Reviews noted that former AAS users who initiate TRT report greater satisfaction with quality-of-life outcomes when their prescribing physicians clearly set expectations around dose targets and the difference between therapeutic and performance-level concentrations [15].

Key Clinical Takeaways for Patients and Clinicians

Former elite bodybuilders who disclose TRT use, as Jay Cutler has, represent a clinically distinct patient group compared with men who develop hypogonadism from aging or illness without prior AAS exposure.

The relevant clinical points for this population:

• Persistent hypogonadism after long-term AAS use is common. The 2021 Journal of Clinical Endocrinology and Metabolism cross-sectional study found 37% of former users remained hypogonadal at a mean of 32 months post-cessation [3].
• Standard Endocrine Society diagnostic thresholds and monitoring protocols apply. The 2018 guideline remains the operative standard of care [6].
• Cardiovascular risk is elevated compared with age-matched men without AAS history. TRAVERSE cardiovascular safety data (HR 1.02, 95% CI 0.82 to 1.28) are reassuring for the general hypogonadal population but were not derived from this higher-risk subgroup [12].
• Dose discipline distinguishes therapy from performance enhancement. Targeting 400 to 700 ng/dL total testosterone mid-interval, with hematocrit checks every three to six months, is the clinically appropriate standard.

Any man with a history of prolonged AAS use who suspects hypogonadism should have two fasting morning testosterone draws, LH, FSH, and a full metabolic panel before any prescribing decision is made.